Leadership & Pay ·
Silexion Therapeutics Corp reported that Professor Amnon Peled resigned from its Board of Directors and all…
SLXNWSilexion Therapeutics Corp
Silexion Therapeutics Corp reported that Professor Amnon Peled resigned from its Board of Directors and all committees, including the audit committee, effective August 1, 2026. The resignation was for personal reasons and not due to disagreements regarding operations or policies. To fill the resulting vacancy, the Board appointed existing independent director Avner Lushi to the audit committee on the same date. Mr. Lushi serves as Managing Partner and CEO of the Guangzhou Sino-Israel Bio-industry Investment Fund and brings extensive board experience in life sciences investments. This appointment restored full compliance with Nasdaq Listing Rule 5605(c)(2)(A) by ensuring the audit committee consists of three independent members, eliminating reliance on any cure period. The company operates in the biotechnology sector.